Regression of Myocardial
amyloidosis
bone tracers
cardiomyopathy
tafamidis
transthyretin
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
21
12
2022
revised:
14
04
2023
medline:
5
7
2023
pubmed:
9
6
2023
entrez:
8
6
2023
Statut:
ppublish
Résumé
Cardiac transthyretin amyloidosis is an infiltrative cardiomyopathy with high mortality. To date, there are no specific biomarkers to directly assess disease activity and response to specific treatments. Our aim was to evaluate scintigraphic changes after treatment with the transthyretin stabilizer tafamidis.
Identifiants
pubmed: 37290801
pii: jnumed.122.265352
doi: 10.2967/jnumed.122.265352
doi:
Substances chimiques
tafamidis
8FG9H9D31J
Prealbumin
0
Organotechnetium Compounds
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1083-1086Informations de copyright
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.